Summary: Barron's Bounce: Andrew Bary explains why the outlook is encouraging for Sarepta's Duchenne muscular dystrophy drug. Plus: Macy's looks undervalued and has GoPro fallen far enough?
Summary: Barron's Bounce: Andrew Bary explains why the outlook is encouraging for Sarepta's Duchenne muscular dystrophy drug. Plus: Macy's looks undervalued and has GoPro fallen far enough?